Enhancing the Built-in Electric Field in Oxygen Vacancies-Enriched I-Doped BiOCl for Visible Light-Driven Photocatalytic Oxidation.

In semiconductor catalysts, rational doping of nonmetallic elements holds significant scientific and technological importance for enhancing photocatalytic performance. Here, using a one-step hydrothermal technique, we synthesized iodine-doped BiOCl composite and evaluated the impact of iodine doping on its photocatalytic capability for organic dye degradation under visible light irradiation. In this study, we demonstrate that the introduction of iodide ions not only provides an ideal built-in electric field (BIEF) for BiOCl but also induces the generation of additional oxygen vacancies (OVs).

Charge-redistributed RuNi/MoN heterojunction enables efficient hydrogen evolution in a wide pH range.

Electrocatalytic hydrogen production offers a promising solution to address current energy depletion. Herein, a RuNi/MoN heterostructure on carbon cloth (CC), RuNi/MoN@CC, was successfully constructed using a simple method, allowing for dual regulation of morphology and electronic structure. Under the influence of Ni, the in-situ generated MoN inherits the morphology of the NiMoO precursor, presenting a nanowire morphology, which is favorable for increasing electrochemical active area.

Microwave replacing traditional concentrating process to promote the synthesis of mumefural in Prunus mume extract.

Mumefural (MF), the primary functional ingredient of prunus mume extract that enhances blood fluidity, is produced by boiling the prunus mume juice for 24-48 h in a traditional one-step concentration process. Low MF yields and long processing time are two disadvantages of this process. This study introduced microwaves into the traditional one-step concentration process of prunus mume extract for increasing MF content.

A new toad of Myers & Leviton, 1962 (Anura, Megophryidae) from Sichuan Province, southwest China.

A new species of the genus Myers & Leviton, 1962 is described from Sichuan Province, southwest China. Molecular phylogenetic analyses based on mitochondrial gene sequences clustered the new species as an independent clade nested with , , and . The new species could be distinguished from its congeners by a combination of the following characters: body size moderate (39.

Modulating adsorption energy on nickel nitride-supported ruthenium nanoparticles through in-situ electrochemical activation for urea-assisted alkaline hydrogen production.

The rational design of electrocatalysts with exceptional performance and durability for hydrogen production in alkaline medium is a formidable challenge. In this study, we have developed in-situ activated ruthenium nanoparticles dispersed on NiN nanosheets, forming a bifunctional electrocatalyst for hydrogen evolution and urea oxidation. The results of experimental analysis and theoretical calculations reveal that the enhanced hydrogen evolution reaction (HER) performance of O-Ru-NiN stems primarily from the optimized hydrogen adsorption and hydroxyl adsorption on Ru sites.

Constructing of CoP-NbO p-n heterojunction with built-in electric field to accelerate the charge migration in electrocatalytic hydrogen evolution.

Studying interfacial charge transfer is of great significance for the preparation of electrocatalysts with high activity for the hydrogen evolution reaction (HER). Particularly, exploring the in-depth catalytic mechanisms and facile fabrication methods of narrow bandgap metal phosphides remains worthwhile. This work successfully combined catalytically inert n-type NbO with p-type CoP to prepare a p-n heterojunction (CoP-NbO).

Engineered Superhydrophilic/Superaerophobic Catalyst: Two-Dimensional Co(OH)-CeO Nanosheets Supported on Three-Dimensional Co Dendrites for Overall Water Splitting.

Efficient electrocatalysts require not only a tunable electronic structure but also great active site accessibility and favorable mass transfer. Here, a two-dimensional/three-dimensional (2D/3D) hierarchical electrocatalyst consisting of Co(OH)-CeO nanosheet-decorated Co dendrites is proposed, named as Co(OH)-CeO/Co. Based on the strong electronic interaction of the Co(OH)-CeO heterojunction, the electronic structure of the Co site is optimized, which facilitates the adsorption of intermediates and the dissociation of HO.

Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid.

The American Association of Pharmaceutical Scientists (AAPS) Chemistry, Manufacturing, and Controls (CMC) Community hosted two virtual panel discussions focusing on several novel regulatory review pathways for innovative oncology products: Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid (PQAAid). The panel sessions were held on August 27, 2021, for the discussion of RTOR, and January 21, 2022, for the discussion of Project Orbis and the PQAAid. Both panel sessions included representatives from the US Food and Drug Administration (FDA) and subject matter experts from the pharmaceutical and biotechnology industries, with the aim of facilitating knowledge sharing on CMC-specific advantages, challenges, eligibility criteria for participation, and operational modifications instituted through the utilization of these acceleration initiatives.

Genome-wide identification of miRNAs and targets associated with cell wall biosynthesis: Differential roles of dlo-miR397a and dlo-miR408-3p during early somatic embryogenesis in longan.

The dynamic alterations in cell wall (CW) biosynthesis play an essential role in physiological isolation during the plant somatic embryogenesis (SE). However, the mechanisms underlying the functions of cell wall-associated miRNAs (CW-miRNA) remain poorly understood in plant SE. Here, we have identified 36 distinct candidate miRNAs associated with CW biosynthesis from longan third-generation genome as well as miRNA transcriptome, and modified RLM-RACE validated four distinct miRNA, which specifically targeted four CW-related genes.

Interface engineering of core-shell NiSe/NiTe electrocatalyst for enhanced oxygen evolution and urea oxidation reactions.

The development of highly efficient oxygen evolution reaction (OER) and urea oxidation reaction (UOR) electrocatalysts with abundant resources is necessary for green hydrogen production. Ni-based compounds have received attention as the most promising earth-abundant electrocatalysts for OER and UOR, whereas some compounds in this main group, e.g.

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.

On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a randomized trial of tivozanib versus sorafenib in patients with R/R advanced RCC. In TIVO-3, patients were randomized to receive either tivozanib 1.

Application of the hospital-family holistic care model in caregivers of patients with permanent enterostomy: A randomized controlled trial.

Aims: To evaluate the effectiveness of the hospital-family holistic care model based on the theory of 'Timing It Right' in caregivers of patients with permanent enterostomy.

Design: A prospective randomized controlled trial.

Methods: One hundred and twenty-five caregivers of patients with permanent enterostomy were recruited from 1 May 2017-31 August 2019.

Acyclovir inhibits channel catfish virus replication and protects channel catfish ovary cells from apoptosis.

The channel catfish virus (CCV) can cause lethal hemorrhagic infection in channel catfish, resulting in significant economic losses in the fish industry. Effective drugs for the virus are still lacking. Acyclovir is known as a potent antiviral agent against human herpes viruses and some animal DNA viruses.

FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.

On April 17, 2020, the FDA approved tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. This was the first new molecular entity evaluated under Project Orbis, an FDA Oncology Center of Excellence initiative, which supports concurrent review of oncology drugs by multiple global health authorities. Approval was based on the HER2CLIMB trial, which randomized patients to receive tucatinib or placebo with trastuzumab and capecitabine.

One-pot synthesis of Mn-Fe bimetallic oxide heterostructures as bifunctional electrodes for efficient overall water splitting.

The design of Earth-abundant and cost-effective electrocatalysts for highly active and stable electrochemical water splitting in practical production is the primary demand. Herein, bimetallic oxides anchored to three-dimensional (3D) porous conductive nickel foam (NF) are constructed using a simple in situ hydrothermal method for efficient overall water splitting. The vertically aligned Mn3O4/Fe2O3 heterojunction nanosheets have synergy between hierarchical metal oxides and heterogeneous interface, and show excellent performance toward the oxygen evolution reaction (OER) and hydrogen evolution reaction (HER) in an alkaline environment.

CuO@Fe-NiS nanoflower in situ grown on copper foam at room temperature as an excellent oxygen evolution electrocatalyst.

Herein, we have synthesized successfully a three-dimensional/two dimensional (3D/2D) core-shell CuO@Fe-NiS nanoflower on copper foam at room temperature. Remarkably, by virtue of rich active sites and vacancies, large surface area, high conductivity and close contact with the electrolyte, the CuO@Fe-NiS catalyst exhibits superior stability and oxygen evolution reaction performance.

Effects of hospital-family holistic care model on the health outcome of patients with permanent enterostomy based on the theory of 'Timing It Right'.

Aims And Objectives: To explore the effects of hospital-family holistic care model based on 'Timing It Right' on the health outcome of patients with permanent colostomy.

Background: Colorectal cancer is a common malignant tumour of digestive system, which seriously threatens human life and health. Colostomy is one of the main treatments for colorectal cancer, which effectively improves the 5-year survival rate of patients.

Prepartum body condition score affects milk yield, lipid metabolism, and oxidation status of Holstein cows.

Objective: This study aimed to investigate the effects of prepartum body condition score (BCS) on the milk yield, lipid metabolism, and oxidative status of Holstein cows.

Methods: A total of 112 multiparous Holstein cows were divided into 4 groups according to the BCS at 21 days before calving: medium BCS (3.0~3.

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections on Type 1 Diabetes Children: A Meta-Analysis of Randomized Control Trials.

Objective: This meta-analysis was performed to evaluate the efficacy and safety of continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) in children with type 1 diabetes.

Methods: A literature search was conducted on databases including PubMed and Embase up to June 2017.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.

The FDA approved niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval was based on data from the NOVA trial comparing niraparib with placebo in two independent cohorts, based on germline mutation status (gm vs. non-gm).

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious Mutation-Associated Advanced Ovarian Cancer.

On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies. The FDA also approved the FoundationFocus CDx test (Foundation Medicine, Inc.